BRAF and uveal melanoma: In addition, the uveal melanoma subtype usually lacks BRAF mutations (Edmunds et al, 2003; Rimoldi et al, 2003), and with the exception of selumetinib, few data exist supporting the use of BRAF or MEK inhibitors in uveal melanoma (Carvajal et al, 2014).